GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumosa Therapeutics Co Ltd (ROCO:6535) » Definitions » ROE % Adjusted to Book Value

Lumosa Therapeutics Co (ROCO:6535) ROE % Adjusted to Book Value : -1.53% (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Lumosa Therapeutics Co ROE % Adjusted to Book Value?

Lumosa Therapeutics Co's ROE % for the quarter that ended in Sep. 2024 was -72.30%. Lumosa Therapeutics Co's PB Ratio for the quarter that ended in Sep. 2024 was 47.28. Lumosa Therapeutics Co's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -1.53%.


Lumosa Therapeutics Co ROE % Adjusted to Book Value Historical Data

The historical data trend for Lumosa Therapeutics Co's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumosa Therapeutics Co ROE % Adjusted to Book Value Chart

Lumosa Therapeutics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.37 -7.48 1.67 -6.70 -1.95

Lumosa Therapeutics Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.53 -3.85 -1.51 0.71 -1.53

Competitive Comparison of Lumosa Therapeutics Co's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Lumosa Therapeutics Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lumosa Therapeutics Co's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lumosa Therapeutics Co's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Lumosa Therapeutics Co's ROE % Adjusted to Book Value falls into.



Lumosa Therapeutics Co ROE % Adjusted to Book Value Calculation

Lumosa Therapeutics Co's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-15.71% / 8.04
=-1.95%

Lumosa Therapeutics Co's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-72.30% / 47.28
=-1.53%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lumosa Therapeutics Co ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Lumosa Therapeutics Co's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Lumosa Therapeutics Co Business Description

Traded in Other Exchanges
N/A
Address
Yuanyuan Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of CNS, oncology, and inflammatory diseases. Geographically, it derives a majority of its revenue from Asia and also has a presence in Taiwan, Europe, and America. Its product pipeline is Neuroscience which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology including LT 2003 for Solid Tumor. It generates revenue from sales of goods.

Lumosa Therapeutics Co Headlines

No Headlines